OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 8
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 8
Showing 8 citing articles:
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
IMPlications of IMP2 in RNA Biology and Disease
J. Das, Ottavia Busia-Bourdain, Khizr M. Khan, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2415-2415
Open Access
J. Das, Ottavia Busia-Bourdain, Khizr M. Khan, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2415-2415
Open Access
Targeting Oncogenic Pathways: Advances in KRAS, CDK, EGFR, and PROTAC-Based Therapies
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2025)
Closed Access
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2025)
Closed Access
HRS-4642: The next piece of the puzzle to keep KRAS in check
Alejandra A. Flores-Gómez, Matthias Drosten
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1157-1159
Closed Access | Times Cited: 3
Alejandra A. Flores-Gómez, Matthias Drosten
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1157-1159
Closed Access | Times Cited: 3
Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1196-1198
Open Access | Times Cited: 1
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1196-1198
Open Access | Times Cited: 1
A New Frontier in Targeted Therapies: Harnessing PROTACs and Advanced Delivery Systems
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 11, pp. 1818-1820
Open Access
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 11, pp. 1818-1820
Open Access
Targeting Cancer: A New Era in Cancer Therapy through Immune Fitness Modulation and KRAS Degradation
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 12, pp. 2074-2076
Open Access
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 12, pp. 2074-2076
Open Access
Suite of Biochemical and Cell-Based Assays for the Characterization of Kirsten Rat Sarcoma (KRAS) Inhibitors and Degraders
Medhanie Kidane, Rene M. Hoffman, Jennifer K. Wolfe-Demarco, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 3921-3934
Open Access
Medhanie Kidane, Rene M. Hoffman, Jennifer K. Wolfe-Demarco, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 3921-3934
Open Access
